<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DABACE4-5A03-427C-AC69-A78C03BD4CA9"><gtr:id>9DABACE4-5A03-427C-AC69-A78C03BD4CA9</gtr:id><gtr:name>Immunobiology Ltd, Babraham, UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F10FB6B-C9C3-4B3B-A91B-AF695129C094"><gtr:id>1F10FB6B-C9C3-4B3B-A91B-AF695129C094</gtr:id><gtr:name>University of Liege</gtr:name><gtr:address><gtr:line1>Place du 20-Aout, 7</gtr:line1><gtr:line4>Liege</gtr:line4><gtr:line5>B-4000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pathology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DABACE4-5A03-427C-AC69-A78C03BD4CA9"><gtr:id>9DABACE4-5A03-427C-AC69-A78C03BD4CA9</gtr:id><gtr:name>Immunobiology Ltd, Babraham, UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F10FB6B-C9C3-4B3B-A91B-AF695129C094"><gtr:id>1F10FB6B-C9C3-4B3B-A91B-AF695129C094</gtr:id><gtr:name>University of Liege</gtr:name><gtr:address><gtr:line1>Place du 20-Aout, 7</gtr:line1><gtr:line4>Liege</gtr:line4><gtr:line5>B-4000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B54F1402-B535-46A3-B1DA-E905717D7FF8"><gtr:id>B54F1402-B535-46A3-B1DA-E905717D7FF8</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Stevenson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BB5BADA1-9405-4B43-8D70-3C71FF3FAFE3"><gtr:id>BB5BADA1-9405-4B43-8D70-3C71FF3FAFE3</gtr:id><gtr:firstName>Stacey</gtr:firstName><gtr:surname>Efstathiou</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ACEA6130-6AFA-47C1-AEED-3D04E24A96EA"><gtr:id>ACEA6130-6AFA-47C1-AEED-3D04E24A96EA</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701185"><gtr:id>729B35FB-AD72-47E1-B043-B57D2F9E38AF</gtr:id><gtr:title>The gammaherpesvirus thymidine kinase</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701185</gtr:grantReference><gtr:abstractText>Herpesviruses are ubiquitous infections and cause many clinical problems in immunosuppressed patients. The most effective treatment to date has been anti-viral drugs such as aciclovir, which exploit a viral enzyme called thymidine kinase (TK). The gamma-herpesviruses have this enzyme, but it is a much weaker enzyme than that of alpha-herpesviruses, against which aciclovir was developed. We suspect that the gamma-herpesvirus TK has different functions, and might therefore best be attacked through different types of drugs.
The human gamma-herpesviruses only infect primates, making many experiments impractical. We are therefore defining what the gamma-herpesvirus TK does using a related murine virus, called MHV-68. We know that the MHV-68 TK is important for viral replication in mice. We aim now to work out why, specifically whether it works in the same way as the alpha-herpesvirus TK, or whether it has very different functions that would be best inhibited in different ways. By understanding how the MHV-68 TK works, we should be able to provide a basis for effective TK-based therapies in gamma-herpesvirus infections.</gtr:abstractText><gtr:technicalSummary>Herpesviruses are major causes of disease. Thymidine kinase (TK)-based therapies have proved very effective against alpha- and beta-herpesviruses. Analogous therapies, combined with lytic cycle induction, are therefore being developed against gamma-herpesviruses. However, it is unclear whether gamma-herpesvirus TKs are equivalent to those of alpha-herpesviruses. They are larger than alpha-herpesvirus TKs, differently distributed in cells, and much less active in nucleoside phosphorylation. Because gamma-herpesviruses do not establish latency in terminally differentiated cells, they may have less need to phosphorylate nucleotides directly for their replication, allowing TK to evolve other functions.
Viral escape mutants inevitably limit the efficacy of drug treatments. It is therefore important for TK-based therapies to understand what role TK plays in gamma-herpesvirus pathogenesis. We also need to improve our basic understanding of these ubiquitous and complex pathogens. Human gamma-herpesviruses lack good experimental lytic replication systems. We and others have therefore developed MHV-68 - a murid gamma-herpesvirus - as a model system for analyzing conserved gamma-herpesvirus lytic gene functions in infected cells and infected animals. TK-deficient MHV-68 is severely attenuated for host colonization. Preliminary data suggest that this reflects a role for TK not in DNA replication in quiescent cells but in viral capsid transport, especially on entry into myeloid cells. This finding has important implications both for how TK-directed therapies might work and for how gamma-herpesviruses normally colonize their hosts.
Our aim now is to define a molecular basis for gamma-herpesvirus TK function, comparing EBV, KSHV and MHV-68. We will focus mainly on virus-infected cells by generating BAC-based MHV-68, EBV and KSHV TK mutants. We will identify how the large N-terminal domain shared by all gamma-herpesvirus TKs contributes to its function, particularly what cellular proteins it interacts with and how its function relates to nucleoside phophorylation. Using MHV-68, we will establish how the molecularly defined TK function explains the dramatic in vivo attenuation of TK-deficient mutants. Our overall aim is to establish a general model of how gamma-herpesvirus TKs work, which should both inform an important area of anti-viral therapy and provide significant new insights into basic gamma-herpesvirus biology.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1029388</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walter and Eliza Hall Institute of Medical Research (WEHI)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Immunology Division</gtr:department><gtr:description>Australia</gtr:description><gtr:id>0434ADDB-B374-4C77-A630-2824D62EBC49</gtr:id><gtr:impact>See publications with G.T.Belz in main list.
Also shared Wellcome Trust project grant.</gtr:impact><gtr:outcomeId>rTwKQsfSzUw-1</gtr:outcomeId><gtr:partnerContribution>Shared resources / projects leading to joint publications</gtr:partnerContribution><gtr:piContribution>Shared resources / projects leading to joint publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunobiology Ltd, Babraham, UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Babraham</gtr:description><gtr:id>BDDD9A52-EFEB-4DBC-B36B-32168B1AE60E</gtr:id><gtr:impact>See joint publication with C.Colaco</gtr:impact><gtr:outcomeId>mQq4gcf2ruH-1</gtr:outcomeId><gtr:partnerContribution>shared PhD student (BBSRC CASE)</gtr:partnerContribution><gtr:piContribution>shared PhD student supervision</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>Portugal</gtr:description><gtr:id>55B042F0-0590-43A3-AE0E-592A67836ADF</gtr:id><gtr:impact>See publications with J.P. Simas in main list</gtr:impact><gtr:outcomeId>D77ScizSDqf-1</gtr:outcomeId><gtr:partnerContribution>Shared resources / projects leading to joint publications</gtr:partnerContribution><gtr:piContribution>Shared resources / projects leading to joint publications.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Cambridge</gtr:description><gtr:id>9689CBE5-EFDA-4F1F-8767-403C314C5E4A</gtr:id><gtr:impact>see joint publications with S.Efstathiou in main list</gtr:impact><gtr:outcomeId>nF2SKiFAgHU-1</gtr:outcomeId><gtr:partnerContribution>joint project</gtr:partnerContribution><gtr:piContribution>worked on joint project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liege</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Laboratory of Immunology - Vaccinology</gtr:department><gtr:description>Belgium</gtr:description><gtr:id>D03C8540-B916-40BF-95D5-A4853D895B1C</gtr:id><gtr:impact>see publications with L.Gillet in main list</gtr:impact><gtr:outcomeId>S8ZAmU5uPH4-1</gtr:outcomeId><gtr:partnerContribution>Shared projects / resources leading to joint publications.</gtr:partnerContribution><gtr:piContribution>Shared projects / resources leading to joint publications</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview for New Scientist</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A23BB938-2E9C-468F-B1EE-071DED402F8A</gtr:id><gtr:impact>Phone interview, transcribed by journalist to contribute to article.

Emails from members of public enquiring about herpesvirus vaccines.</gtr:impact><gtr:outcomeId>p9jkCdRrzp1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>naked scientist</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>4280F466-8D6A-4914-9BB3-A0F61DBA2F00</gtr:id><gtr:impact>Question and answer session on radio.

audience showed interest</gtr:impact><gtr:outcomeId>UzNKFxVXC43</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>interview</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>C0C9E190-554A-40BE-99A3-C2DCCFD8175F</gtr:id><gtr:impact>telephone interview with journalist

web interest</gtr:impact><gtr:outcomeId>JKdh4du1GqM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department open day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F0812B9B-6CDE-4AEC-AC83-946442B6C4CC</gtr:id><gtr:impact>Engaged with public, explaining research in the department and its context. Also built some models of viruses.

Better public understanding of science.</gtr:impact><gtr:outcomeId>ED3C4AF788C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>608871</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Comprehensive mapping of rhadinovirus dissemination and persistence</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J014419/1</gtr:fundingRef><gtr:id>F230D6DF-C9B8-4ACD-91C2-316B6B05B520</gtr:id><gtr:outcomeId>bvNMyX4yNC9</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>BELVIR collaborative grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Fund for Scientific Research (NFSR)</gtr:fundingOrg><gtr:id>562107E2-EBB5-4EDD-B32E-F3067886C473</gtr:id><gtr:outcomeId>J9vf8TeyqN9</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust project grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>D9E4B4DF-2B89-4650-98A4-56FB10EC2B5C</gtr:id><gtr:outcomeId>aANdJj1NgmC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>generated knockout + fluorescent tagged viruses</gtr:description><gtr:id>EDBABEB9-CAF8-41E9-BC88-E2991C32AC51</gtr:id><gtr:impact>publications from other labs (we do not request joint authorship for providing published reagents)</gtr:impact><gtr:outcomeId>iqVmh6wEgyU</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>knockout viruses</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>monoclonal antibodies to KSHV and EBV thymidine kinases</gtr:description><gtr:id>E731B858-A58C-4AEB-A16B-7499B3896550</gtr:id><gtr:impact>unknown as yet</gtr:impact><gtr:outcomeId>3E45B75E86A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>generation of monoclonal antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A26F9341-8A91-4397-ABEE-1837664E044C</gtr:id><gtr:title>In vivo imaging of murid herpesvirus-4 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b0387eb8585a972c2034e714f5ac9ae"><gtr:id>1b0387eb8585a972c2034e714f5ac9ae</gtr:id><gtr:otherNames>Milho R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>CA40CA51125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93B6DEBD-CB8D-479D-9A95-CF55C25C97BE</gtr:id><gtr:title>Glycoprotein B cleavage is important for murid herpesvirus 4 to infect myeloid cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_540e157e157a41341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>726A9084-B679-4469-B8D5-616FF078F462</gtr:id><gtr:title>Glycoprotein L sets the neutralization profile of murid herpesvirus 4.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>9BCA736F390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA54A24-7F51-4044-980E-DF77EA01EFD2</gtr:id><gtr:title>Comparative study of murid gammaherpesvirus 4 infection in mice and in a natural host, bank voles.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04d2283dc200b3ae73a0d376bca576dd"><gtr:id>04d2283dc200b3ae73a0d376bca576dd</gtr:id><gtr:otherNames>Fran?ois S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>WF4mS1xgmvB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC9CED08-5418-46BE-8445-AFD3EBF881A3</gtr:id><gtr:title>Bovine herpesvirus type 4 glycoprotein L is nonessential for infectivity but triggers virion endocytosis during entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbcde25aa7a106f9c49a0a9e6c9ff53e"><gtr:id>dbcde25aa7a106f9c49a0a9e6c9ff53e</gtr:id><gtr:otherNames>L?t? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13488_28_22205754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48E7FF2E-19FD-4BA8-A86D-D0DC811E7D90</gtr:id><gtr:title>Herpesvirus glycoproteins undergo multiple antigenic changes before membrane fusion.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13488_28_22253913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BE0F7A5-2FF5-49B1-83D0-AF454B75D679</gtr:id><gtr:title>Murid herpesvirus-4 exploits dendritic cells to infect B cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f25d0b0c3441d39861c4c4befbc085c"><gtr:id>8f25d0b0c3441d39861c4c4befbc085c</gtr:id><gtr:otherNames>Gaspar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>XJw5zo2VYeb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F11F662-B067-4B51-AC50-10F7AA03EA76</gtr:id><gtr:title>Antibody evasion by a gammaherpesvirus O-glycan shield.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ffa43406a00d29d36be74a8fe00b56"><gtr:id>04ffa43406a00d29d36be74a8fe00b56</gtr:id><gtr:otherNames>Machiels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>A9X4tMLNdC6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4A3FDCA-DAAF-4402-BBF8-51940212329E</gtr:id><gtr:title>Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c05e7f57cadf260a1234bb1642ccda3"><gtr:id>8c05e7f57cadf260a1234bb1642ccda3</gtr:id><gtr:otherNames>Frederico B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13488_28_23028329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D520D32-9E5B-4DD0-923E-FB29D7E79E95</gtr:id><gtr:title>The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ffa43406a00d29d36be74a8fe00b56"><gtr:id>04ffa43406a00d29d36be74a8fe00b56</gtr:id><gtr:otherNames>Machiels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>DFfVZiFCprF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EBF5102-C73A-43E8-A282-FB8FD96A2BF6</gtr:id><gtr:title>A mechanistic basis for potent, glycoprotein B-directed gammaherpesvirus neutralization.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>gqPc7YFCHeR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94968782-2F8D-41E1-AFAD-C05CF6C69C4E</gtr:id><gtr:title>KSHV-TK is a tyrosine kinase that disrupts focal adhesions and induces Rho-mediated cell contraction.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0697c0cd0fc47286f423f42c1dad0197"><gtr:id>0697c0cd0fc47286f423f42c1dad0197</gtr:id><gtr:otherNames>Gill MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>5639601ddca810.20615161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C30C2F2-A01C-4523-99A7-0F641D0B5381</gtr:id><gtr:title>Herpes simplex virus 1 targets the murine olfactory neuroepithelium for host entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf94895527f4d9079912aefafbd34d31"><gtr:id>cf94895527f4d9079912aefafbd34d31</gtr:id><gtr:otherNames>Shivkumar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_540e157e157af31bb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6B23E89-45FF-4B9F-B15D-00997E3DC7AD</gtr:id><gtr:title>Multiple functions for ORF75c in murid herpesvirus-4 infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f25d0b0c3441d39861c4c4befbc085c"><gtr:id>8f25d0b0c3441d39861c4c4befbc085c</gtr:id><gtr:otherNames>Gaspar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>70EA77C0935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03DE3B05-947F-4AAA-AEB8-53443445145E</gtr:id><gtr:title>In vivo function of the murid herpesvirus-4 ribonucleotide reductase small subunit.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b0387eb8585a972c2034e714f5ac9ae"><gtr:id>1b0387eb8585a972c2034e714f5ac9ae</gtr:id><gtr:otherNames>Milho R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5464a60d1c25a0.89491459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66BBA7B0-CF7F-47FA-85AC-C3D5729D120B</gtr:id><gtr:title>Important role for the murid herpesvirus 4 ribonucleotide reductase large subunit in host colonization via the respiratory tract.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0697c0cd0fc47286f423f42c1dad0197"><gtr:id>0697c0cd0fc47286f423f42c1dad0197</gtr:id><gtr:otherNames>Gill MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5464a60cec2b72.52785208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2071294-D307-4EC7-9F53-C62E3C474EE6</gtr:id><gtr:title>Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4edff9882d92d6a573bbae0574f1be1a"><gtr:id>4edff9882d92d6a573bbae0574f1be1a</gtr:id><gtr:otherNames>Stevenson PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>D7544B19808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8795C4CA-544A-415F-B95E-6E0C7E760D2B</gtr:id><gtr:title>An in vitro system for studying murid herpesvirus-4 latency and reactivation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae4bda5e05b638f9857b4ea3568e7ae"><gtr:id>4ae4bda5e05b638f9857b4ea3568e7ae</gtr:id><gtr:otherNames>May JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RnHGjaM68cq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD4F8DCC-BB41-449B-A14B-4959E7E8B6DD</gtr:id><gtr:title>Interference with dendritic cell populations limits early antigen presentation in chronic ?-herpesvirus-68 infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0ce72af7ff2f3a55e63c2179e3e5983"><gtr:id>b0ce72af7ff2f3a55e63c2179e3e5983</gtr:id><gtr:otherNames>Mount AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pvB5t2FCEhe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88535F51-A1B4-44DF-94BF-3C6B8AE07194</gtr:id><gtr:title>Murid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0697c0cd0fc47286f423f42c1dad0197"><gtr:id>0697c0cd0fc47286f423f42c1dad0197</gtr:id><gtr:otherNames>Gill MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>1138B211DEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09D15963-CF1E-446D-AA38-EF14E78B5430</gtr:id><gtr:title>Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6443a5725925c7ca9e2f2eff6883e779"><gtr:id>6443a5725925c7ca9e2f2eff6883e779</gtr:id><gtr:otherNames>Wright DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>13CCF63D339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0956CE-F44C-4FF6-A838-5C23129A7788</gtr:id><gtr:title>Virion endocytosis is a major target for murid herpesvirus-4 neutralization.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_13488_28_22377583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>936E41F1-1554-4B71-9820-5F43757305BB</gtr:id><gtr:title>Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralization.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae4bda5e05b638f9857b4ea3568e7ae"><gtr:id>4ae4bda5e05b638f9857b4ea3568e7ae</gtr:id><gtr:otherNames>May JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>co5mZia9p3z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC104FEE-B424-47E8-8FD8-2893F0D21D36</gtr:id><gtr:title>In vivo imaging of murid herpesvirus-4 infection</gtr:title><gtr:parentPublicationTitle>JOURNAL OF GENERAL VIROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/583316fbe82cc9a51f26865451289ec4"><gtr:id>583316fbe82cc9a51f26865451289ec4</gtr:id><gtr:otherNames>Milho Ricardo</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>doi_55faa1aa1d32f069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>288E4788-C5B5-4ED3-B83A-D11A1DCDEC3A</gtr:id><gtr:title>Vaccination against a hit-and-run viral cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4edff9882d92d6a573bbae0574f1be1a"><gtr:id>4edff9882d92d6a573bbae0574f1be1a</gtr:id><gtr:otherNames>Stevenson PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>JNdbrjQYzPE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B131EBB7-125F-4C4F-850D-0D62C3B0A6A2</gtr:id><gtr:title>A heparan-dependent herpesvirus targets the olfactory neuroepithelium for host entry.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b0387eb8585a972c2034e714f5ac9ae"><gtr:id>1b0387eb8585a972c2034e714f5ac9ae</gtr:id><gtr:otherNames>Milho R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13488_28_23133384</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701185</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>